Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 12/2011

01-08-2011 | Review Article

Once-Versus Twice-Daily Tacrolimus

Are the Formulations Truly Equivalent?

Authors: Dr Katherine A. Barraclough, Nicole M. Isbel, David W. Johnson, Scott B. Campbell, Christine E. Staatz

Published in: Drugs | Issue 12/2011

Login to get access

Abstract

Tacrolimus is a cornerstone immunosuppressant agent in the prevention of organ rejection following transplantation. While typically administered twice daily (Prograf®), a modified-release once-daily formulation (Advagraf®) has recently been developed and licensed for use. To date, the majority of published data relating to the use of Advagraf® have arisen from industry-sponsored clinical trials. These have shown that conversion from Prograf® to Advagraf® on a 1 mg: 1 mg basis in both stable and de novo kidney and liver transplant recipients yields lower peak concentrations (Cmax) but equivalent overall drug exposure (area under the concentration-time curve from 0 to 24 hours post-dose; AUC24) and trough concentrations (Cmin). This has led to the proposal that the same total daily dose, target Cmin and therapeutic drug monitoring (TDM) strategies can be applied irrespective of preparation. However, while Advagraf® fulfils criteria for bioequivalence according to the European Medicines Agency and US FDA, lower tacrolimus exposure has been observed in the majority of clinical studies, particularly in the early post-transplant period. This has resulted in a need for higher doses of Advagraf® compared with Prograf® to achieve similar Cmin values. Significant between-subject variability in the Cmin/AUC24 relationship with Advagraf® has also been demonstrated, suggesting possible problems with TDM based on Cmin values. In non-comparative conversion studies, Advagraf® demonstrated similar efficacy and safety to Prograf®. However, phase III studies in de novo kidney and liver transplant recipients have shown higher rates of acute rejection with Advagraf®, possibly explained by the differing Cmax values achieved with the two preparations. While it has been suggested that once-daily administration may improve compliance, no studies have proven this to be the case. This article reviews the pharmacokinetics, efficacy, adverse effects and utility of Advagraf® in relation to its equivalence to Prograf®, and areas that require additional research are identified.
Literature
1.
2.
3.
4.
First MR. First clinical experience with the new once-daily formulation of tacrolimus. Ther Drug Monit 2008 Apr; 30(2): 159–66PubMedCrossRef
5.
First MR, Fitzsimmons WE. Modified release tacrolimus. Yonsei Med J 2004 Dec 31; 45(6): 1127–31PubMed
6.
7.
Staatz CE, Tett SE. Clinical pharmacokinetics and phar-macodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43(10): 623–53PubMedCrossRef
8.
Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 2005 Mar; 37(2): 867–70PubMedCrossRef
9.
Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc 2005 Mar; 37(2): 1211–3PubMedCrossRef
10.
Alloway R, Vanhaecke J, Undre N. Conversion of stable heart transplant recipients from twice daily prograf to once daily modified release tacrolimus. Transpl Int 2005; 18 Suppl. 1: 75
11.
Heffron TG, Pescovitz MD, Florman S, et al. Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. Am J Transplant 2007 Jun; 7(6): 1609–15PubMedCrossRef
12.
Diez Ojea B, Alonso Alvarez M, Aguado Fernandez S, et al. Three-month experience with tacrolimus once-daily regimen in stable renal allografts. Transplant Proc 2009 Jul—Aug; 41(6): 2323–5PubMedCrossRef
13.
Gallego-Valcarce E, Ortega-Cerrato A, Llamas-Fuentes F, et al. Conversion to tacrolimus extended-release formulation: short-term clinical results. Transplant Proc 2009 Jul–Aug; 41(6): 2326–7PubMedCrossRef
14.
Marin-Gomez LM, Gomez-Bravo MA, Alamo-Martinez JA, et al. Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study. Transplant Proc 2009 Jul-Aug; 41(6): 2184–6PubMedCrossRef
15.
de Jonge H, Kuypers DR, Verbeke K, et al. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation2010 Sep 15; 90(5): 523–9PubMedCrossRef
16.
Wehland M, Bauer S, Brakemeier S, et al. Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharma-cogenet Genomics 2011 Apr; 21(4): 179–84
17.
Merli M, Di Menna S, Giusto M, et al. Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient. TransplantProc 2010 May;42(4): 1322–4CrossRef
18.
Marzoa-Rivas R, Paniagua-Martin MJ, Barge-Caballero E, et al. Conversion of heart transplant patients from standard to sustained-release tacrolimus requires a dosage increase. Transplant Proc 2010 Oct; 42(8): 2994–6PubMedCrossRef
19.
Mecule A, Poli L, Nofroni I, et al. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. Transplant Proc 2010 May; 42(4): 1317–9PubMedCrossRef
20.
Comuzzi C, Lorenzin D, Rossetto A, et al. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients. Transplant Proc 2010 May; 42(4): 1320–1PubMedCrossRef
21.
Iaria G, Sforza D, Angelico R, et al. Switch from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (advagraf) in kidney transplantation. Transplant Proc 2011 May; 43(4): 1028–9PubMedCrossRef
22.
Hougardy JM, Broeders N, Kianda M, et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation 2011 Mar 15; 91(5): 566–9PubMedCrossRef
23.
24.
Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for once-versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 2009 Nov; 9(11): 2505–13PubMedCrossRef
25.
Undre NA. Use of a once daily modified release tacrolimus regimen in de novo liver transplant recipients [abstract no. 859]. Am J Transplant 2005; 5 Suppl. 5: 374
26.
Kramer BK, Charpentier B, Backman L, et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant 2010 Dec; 10(12): 2632–43PubMedCrossRef
27.
Andres A, Delgado-Arranz M, Morales E, et al. Extended-release tacrolimus therapy in de novo kidney transplant recipients: single-center experience. Transplant Proc 2010 Oct; 42(8): 3034–7PubMedCrossRef
28.
Crespo M, Mir M, Marin M, et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant Proc 2009 Jul–Aug; 41(6): 2115–7PubMedCrossRef
29.
Jelassi ML, Lefeuvre S, Karras A, et al. Therapeutic drug monitoring in de novo kidney transplant receiving the modified-release once-daily tacrolimus. Transplant Proc 2011 Mar; 43(2): 491–4PubMedCrossRef
30.
Trunecka P, Boillot O, Seehofer D, et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant 2010 Oct; 10(10): 2313–23PubMedCrossRef
31.
Silva Jr HT, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007 Mar; 7(3): 595–608PubMedCrossRef
32.
Cabello M, Garcia P, Gonzalez-Molina M, et al. Pharmacokinetics of once-versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. Transplant Proc 2010 Oct; 42(8): 3038–40PubMedCrossRef
33.
Saint-Marcoux F, Debord J, Undre N, et al. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. Ther Drug Monit 2010 Apr; 32(2): 129–35PubMed
34.
Benkali K, Rostaing L, Premaud A, et al. Population pharmacokinetics and bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet 2010 Oct 1; 49(10): 683–92PubMedCrossRef
35.
Canaparo R, Finnstrom N, Serpe L, et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin Exp Pharmacol Physiol 2007 Nov; 34(11): 1138–44PubMed
36.
Glowacki F, Lionet A, Hammelin JP, et al. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. Clin Pharmacokinet 2011 Jul 1; 50(7): 451–9PubMedCrossRef
37.
van Hooff JP, Alloway RR, Trunecka P, et al. Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies. Clin Transplant2011 Jan–Feb; 25(1): E1–12PubMedCrossRef
38.
Florman S, Alloway R, Kalayoglu M, et al. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation 2007 Jun 27; 83(12): 1639–42PubMedCrossRef
39.
Alloway R, Steinberg S, Khalil K, et al. Two years post-conversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation 2007 Jun 27; 83(12): 1648–51PubMedCrossRef
40.
Heffron TG. A two year follow-up of stable pediatric liver transplant recipients converted from a twice daily Prograf based regimen to a once daily extended release tacrolimus based regimen [abstract no. 777]. Am J Transplant 2007; Suppl. 2: 348
41.
Grant D, Kneteman N, Tchervenkov J, et al. Peak cyclo-sporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Transplantation 1999 Apr 27; 67(8): 1133–7PubMedCrossRef
42.
Ishibashi M, Yoshida K, Ozono S, et al. Experimental study of tacrolimus immunosuppression on the mode of administration: efficacy of constant intravenous infusion avoiding C(max). Transplant Proc 2001 Feb-Mar; 33(1-2): 559–60PubMedCrossRef
43.
Tada H, Satoh S, Iinuma M, et al. Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. J Clin Pharmacol 2003 Aug; 43(8): 859–65PubMedCrossRef
44.
Braun F, Schutz E, Peters B, et al. Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. Transplant Proc 2001 May; 33(3): 2127–8PubMedCrossRef
45.
Kimikawa M, Kamoya K, Toma H, et al. Effective oral administration of tacrolimus in renal transplant recipients. Clin Transplant 2001 Oct; 15(5): 324–9PubMedCrossRef
46.
Pisitkun T, Eiam-Ong S, Chusil S, et al. The roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients. Transplant Proc 2002 Dec; 34(8): 3173–5PubMedCrossRef
47.
Bottiger Y, Undre NA, Sawe J, et al. Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. Transplant Proc 2002 Aug; 34(5): 1544–5PubMedCrossRef
48.
Wong KM, Shek CC, Chau KF, et al. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis 2000 Apr; 35(4): 660–6PubMedCrossRef
49.
Stolk LM, Van Duijnhoven EM, Christiaans MH, et al. Trough levels of tacrolimus [letter]. Ther Drug Monit 2002 Aug; 24(4): 573; author reply 573-4PubMedCrossRef
50.
Mathew BS, Fleming DH, Jeyaseelan V, et al. A limited sampling strategy for tacrolimus in renal transplant patients. Br J Clin Pharmacol 2008 Oct; 66(4): 467–72PubMedCrossRef
51.
Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995 Mar; 57(3): 281–90PubMedCrossRef
52.
Jorgensen K, Povlsen J, Madsen S, et al. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant 2002 Aug; 17(8): 1487–90PubMedCrossRef
53.
Cantarovich M, Fridell J, Barkun J, et al. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. Transplant Proc 1998 Jun; 30(4): 1460–1PubMedCrossRef
54.
Armendariz Y, Pou L, Cantarell C, et al. Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit 2005 Aug; 27(4): 431–4PubMedCrossRef
55.
Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009 Apr; 31(2): 139–52PubMedCrossRef
56.
Woillard JB, de Winter BC, Kamar N, et al. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations: twice daily prograf and once daily advagraf. Br J Clin Pharmacol 2011 Mar; 71(3): 391–402PubMedCrossRef
57.
Woywodt A, Delargy M, Thain Z. Different preparations of tacrolimus and medication errors [letter]. Am J Transplant 2008 Sep; 8(9): 1962PubMedCrossRef
58.
59.
60.
The Institute for Safe Medication Practices Canada. Prograf and Advagraf mix-up. Can J Hosp Pharm 2009; 62(5): 417–8
Metadata
Title
Once-Versus Twice-Daily Tacrolimus
Are the Formulations Truly Equivalent?
Authors
Dr Katherine A. Barraclough
Nicole M. Isbel
David W. Johnson
Scott B. Campbell
Christine E. Staatz
Publication date
01-08-2011
Publisher
Springer International Publishing
Published in
Drugs / Issue 12/2011
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11593890-000000000-00000

Other articles of this Issue 12/2011

Drugs 12/2011 Go to the issue

Therapy in Practice

Acute Myeloid Leukaemia

Therapy in Practice

Management of Recurrent Head and Neck Cancer

Adis Drug Evaluation

Live Attenuated Influenza Vaccine (FluMist®; Fluenz™)

Adis Drug Profile

Nilotinib

Adis Drug Evaluation

Plerixafor

Erratum

Erratum to: Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer